Please login to the form below

Not currently logged in

Bayer enters agreement with Celera

Bayer Schering Pharma AG, Germany, has entered into an exclusive licence agreement with US biotech company Celera Corporation

Bayer Schering Pharma AG, Germany, has entered into an exclusive licence agreement with US biotech company Celera Corporation. Bayer will pay Celera a one-off fee for exclusive access to five cancer target molecules and additional payments for particular development and commercial milestones. Celera will also receive royalties based on net sales of commercialised products.

"We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumour therapy as well as in in-vivo diagnostic imaging", said Professor Khusru Asadullah head of target discovery at Bayer Schering Pharma. 

Celera Genomics was founded in 1988 with the aim of sequencing and assembling the human genome. It was acquired by Applera Corporation but separated from that company and started trading on Nasdaq in July 2008. It recently moved its base from Maryland Washington, to Alameda, California and is now focused on developing personalised diagnostics and medicines. Steve Ruben, vice president of proteomic research at the company, said: "This agreement combines the strength of our novel proteomics target discovery platform with Bayer Schering Pharma's expertise in research and development." 

30th June 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...